Mesoblast Limited (ASX:MSB) has received clearance to begin trialling a drug that the company says has the great potential to improve the quality of life for patients suffering acute heart attacks.
The European Medicines Agency has given the company the green light to begin a 225 patient trial in Europe for its lead cardiovascular product, Revascor.
The off-the-shelf adult stem-cell product trial will last for about 36 months.
The lead investigator of the product in the UK, Dr Jonathan Hill, says the drug has the potential to change the medical paradigm for treatment of large heart attacks.
If preclinical results are reproduced in the trial, Mesoblast will commercialise the drug through US biopharmaceutical company Cephalon Incorporated.
Mesoblast Limited (ASX:MSB) reported a profit of $90.6 million for the half year to June this year.
